ASCO policy statement on biosimilar and interchangeable products in oncology

12 April 2023 - Given the current market dynamics and the regulatory landscape, this ASCO manuscript now seeks to propose several ...

Read more →

Outcome statement - February 2023 DUSC meeting

31 March 2023 - The outcome statement from the February 2023 DUSC meeting is now available. ...

Read more →

Boom in scripts to fight depression

22 December 2022 - The explosion in popularity of the drugs comes despite warnings from psychiatrists that ­antidepressants should not be ...

Read more →

Outcome statement - September 2022 DUSC meeting

3 November 2022 - The outcome statement from the September 2022 DUSC meeting is now available. ...

Read more →

DUSC utilisation analysis public release documents (October 2022)

25 October 2022 - The utilisation analysis public release documents from the June 2022 DUSC meeting are now available. ...

Read more →

Saskatchewan becomes sixth Canadian province to implement a biosimilar switching policy

21 October 2022 - Saskatchewan joined five provinces and one territory in implementing a biosimilar switching policy, allowing for reference ...

Read more →

Amgen's annual trends report finds competition created by biosimilars contributed $21 billion in US health care system savings

12 October 2022 - Ninth Edition of Amgen's Biosimilar Trends Report Examines the U.S. and Global Marketplace with Biosimilars. ...

Read more →

Continued development of the national health data registers leads to better follow-up of medicines

3 October 2022 - The Dental and Pharmaceutical Benefits Agency (TLV) is today handing over a report to the government on ...

Read more →

Novavax appeals to ATAGI to change advice as vaccine uptake falls behind

25 September 2022 - Novavax was hailed as the fix to Australia’s low inoculation rate and “the vaccine for anti-vaxxers”. So ...

Read more →

13 million Novavax doses due to expire as Australians stick to mRNA boosters

21 September 2022 - Novavax COVID vaccines procured by the federal government in the hopes of convincing hesitant Australians to ...

Read more →

Pharmaceutical Benefits Scheme supplied medications

30 August 2022 - Key findings about health and population characteristics from the National Health Survey (NHS) and the Pharmaceutical Benefits ...

Read more →

U.S. prescription drug market lacks certain competitive features: case of biosimilars

3 August 2022 - In a legal ruling reported yesterday, a 7th Circuit Court Federal Judge, Frank Easterbrook, affirmed dismissal of ...

Read more →

Biosimilar uptake accelerates in US—and so do the savings

13 July 2022 - Amgen's early view said health care savings from the use of these biologic therapies climbed to ...

Read more →

Drug Utilisation SubCommittee outcome statement

8 July 2022 - The outcome statement from the June 2022 DUSC meeting is now available. ...

Read more →

NHS saves 1.2 billion pounds on medicines over three years

1 July 2022 - The NHS has saved taxpayers £1.2 billion in just three years, while securing cutting-edge treatments for ...

Read more →